These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11801553)

  • 1. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.
    Holten-Andersen MN; Christensen IJ; Nielsen HJ; Stephens RW; Jensen V; Nielsen OH; Sørensen S; Overgaard J; Lilja H; Harris A; Murphy G; Brünner N
    Clin Cancer Res; 2002 Jan; 8(1):156-64. PubMed ID: 11801553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
    Holten-Andersen MN; Murphy G; Nielsen HJ; Pedersen AN; Christensen IJ; Høyer-Hansen G; Brünner N; Stephens RW
    Br J Cancer; 1999 May; 80(3-4):495-503. PubMed ID: 10408859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
    Frederiksen C; Lykke J; Christensen IJ; Brünner N; Nielsen HJ
    Scand J Clin Lab Invest; 2007; 67(5):545-52. PubMed ID: 17763191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
    Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
    Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
    Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
    Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer.
    Hammer JH; Basse L; Svendsen MN; Werther K; Brünner N; Christensen IJ; Nielson HJ
    Colorectal Dis; 2006 Mar; 8(3):168-72. PubMed ID: 16466554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
    Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ
    Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
    Wang CS; Wu TL; Tsao KC; Sun CF
    Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
    Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
    Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
    Larsen MB; Stephens RW; Brünner N; Nielsen HJ; Engelholm LH; Christensen IJ; Stetler-Stevenson WG; Høyer-Hansen G
    Scand J Immunol; 2005 May; 61(5):449-60. PubMed ID: 15882437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
    Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
    Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
    Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
    Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
    BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations.
    Lomholt AF; Frederiksen CB; Christensen IJ; Brünner N; Nielsen HJ
    Clin Chim Acta; 2007 May; 380(1-2):128-32. PubMed ID: 17328880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T
    Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying markers for pancreatic cancer by gene expression analysis.
    Zhou W; Sokoll LJ; Bruzek DJ; Zhang L; Velculescu VE; Goldin SB; Hruban RH; Kern SE; Hamilton SR; Chan DW; Vogelstein B; Kinzler KW
    Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):109-12. PubMed ID: 9488584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.